---
title: Antiviral Drugs
type: content
phase: 1
status: complete
priority: high
tags: [antivirals, HIV, hepatitis, influenza, herpes, acyclovir, oseltamivir, antiretrovirals, DAAs]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antiviral Drugs

## Introduction

Antiviral therapy has revolutionized the treatment of viral infections, transforming previously fatal conditions like HIV into manageable chronic diseases. Unlike bacteria, viruses are obligate intracellular parasites that utilize host cell machinery, making selective toxicity challenging. Understanding viral replication cycles and drug mechanisms is essential for effective therapy.

## Core Concepts

### Viral Replication Cycle

1. **Attachment and Entry**: Virus binds to cell surface receptors
2. **Uncoating**: Release of viral genome into cytoplasm
3. **Replication**: Viral DNA/RNA synthesis
4. **Protein Synthesis**: Translation of viral proteins
5. **Assembly**: Packaging of viral genome and proteins
6. **Release**: Budding or lysis of host cell

**Antiviral targets**: Each step can be targeted

### Challenges in Antiviral Therapy

- Intracellular replication (drug must enter cells)
- Dependence on host machinery (limited selective toxicity)
- Rapid mutation (resistance development)
- Latency (some viruses hide in host genome)

---

## Anti-Herpes Drugs

### Acyclovir (Zovirax)

**Mechanism**:
- **Prodrug**: Requires viral thymidine kinase for activation
- Phosphorylated to acyclovir triphosphate
- Inhibits viral DNA polymerase
- Acts as DNA chain terminator
- **Selectivity**: Viral thymidine kinase >> cellular kinase

**Spectrum**:
- **HSV-1, HSV-2** (herpes simplex)
- **VZV** (varicella-zoster virus)
- Less active against EBV, CMV

**Pharmacokinetics**:
- **Oral, IV, topical**
- **Poor oral bioavailability** (~20%)
- **Renal excretion** (dose adjustment required)
- Good CSF penetration

**Clinical Uses**:
- **Genital herpes**: Initial episode, recurrent episodes, suppression
- **HSV encephalitis** (IV acyclovir)
- **Herpes zoster** (shingles)
- **Varicella** (chickenpox) in immunocompromised
- **Neonatal HSV**

**Dosing**:
- Oral: 200-800 mg, 2-5 times daily (varies by indication)
- IV: 5-10 mg/kg q8h (severe infections)

**Adverse Effects**:
- **Nephrotoxicity** (IV):
  - Crystal deposition in renal tubules
  - Prevention: Hydration, slow infusion
- **Neurotoxicity** (high-dose IV): Confusion, tremor, seizures (renal impairment)
- **Phlebitis** (IV)
- GI upset (oral)

**Resistance**:
- Thymidine kinase-deficient mutants (most common)
- DNA polymerase mutations

**Clinical Pearls**:
1. **Drug of choice** for HSV encephalitis
2. **Hydration essential** with IV use
3. **Suppressive therapy**: Reduces recurrent genital herpes
4. **Pregnancy Category B**: Safe in pregnancy

### Valacyclovir (Valtrex)

- **Prodrug of acyclovir** (L-valyl ester)
- **Better oral bioavailability** (~55% vs. 20%)
- Converted to acyclovir by first-pass metabolism
- Same spectrum, uses, adverse effects
- **Dosing**: Less frequent (BID-TID vs. 5×/day)
- Preferred for oral therapy (better compliance)

### Famciclovir (Famvir)

- **Prodrug of penciclovir**
- Similar to acyclovir mechanism
- **Better oral bioavailability** than acyclovir
- Same indications as valacyclovir
- TID dosing

### Ganciclovir (Cytovene)

**Mechanism**:
- Similar to acyclovir
- Activated by viral kinase (CMV UL97)
- Inhibits viral DNA polymerase

**Spectrum**:
- **CMV** (cytomegalovirus) - much more active than acyclovir
- Also active against HSV, VZV

**Pharmacokinetics**:
- **IV** (poor oral bioavailability)
- **Intravitreal implant** for CMV retinitis
- Renal excretion

**Clinical Uses**:
- **CMV retinitis** (AIDS)
- **CMV prophylaxis** (transplant recipients)
- **CMV pneumonitis, colitis, esophagitis**

**Adverse Effects**:
- **Bone marrow suppression** (major toxicity):
  - Neutropenia (40%)
  - Thrombocytopenia, anemia
  - Monitor CBC frequently
- **Nephrotoxicity**
- **Teratogenic, carcinogenic** (black box warnings)
- **Male infertility** (azoospermia)

**Contraindications**:
- ANC <500/mm³
- Platelet count <25,000/mm³

**Monitoring**:
- **CBC**: 2-3 times/week

### Valganciclovir (Valcyte)

- **Prodrug of ganciclovir** (L-valyl ester)
- **Excellent oral bioavailability** (~60%)
- Allows outpatient CMV therapy
- Same spectrum, uses, toxicity as ganciclovir
- Preferred for prophylaxis and maintenance

### Foscarnet (Foscavir)

**Mechanism**:
- **Direct** viral DNA/RNA polymerase inhibitor
- **Does NOT require activation** (no kinase needed)
- Pyrophosphate analog

**Spectrum**:
- CMV, HSV, VZV
- **HIV** (reverse transcriptase inhibition)

**Clinical Uses**:
- **Acyclovir-resistant HSV/VZV**
- **Ganciclovir-resistant CMV**
- CMV retinitis (alternative)

**Adverse Effects**:
- **Nephrotoxicity** (major):
  - Acute tubular necrosis
  - Requires aggressive hydration
- **Electrolyte abnormalities**:
  - **Hypo/hypercalcemia**
  - **Hypo/hyperphosphatemia**
  - **Hypomagnesemia**
  - **Hypokalemia**
- Genital ulcerations (irritation)
- **Seizures**

**Monitoring**:
- **Electrolytes**: Frequently (Ca2+, Mg2+, PO4, K+)
- **Renal function**: SCr, BUN

**Clinical Pearls**:
1. **Reserved for resistant virus**
2. **Aggressive hydration**: Essential to prevent nephrotoxicity
3. **Electrolyte monitoring**: Critical

### Cidofovir

- Broad-spectrum antiviral
- **Severe nephrotoxicity**: Limits use
- Requires probenecid + IV hydration
- Reserved for resistant CMV, progressive multifocal leukoencephalopathy (PML)

---

## Anti-Influenza Drugs

### Neuraminidase Inhibitors

**Mechanism**:
- Inhibit viral **neuraminidase**
- Prevent release of progeny virions from infected cells
- Block spread of infection

#### Oseltamivir (Tamiflu)

**Pharmacokinetics**:
- **Oral** (prodrug)
- Activated by hepatic esterases
- Renal excretion

**Clinical Uses**:
- **Treatment**: Influenza A and B (within 48 hours of symptom onset)
- **Prophylaxis**: During outbreaks, high-risk contacts

**Efficacy**:
- Reduces symptom duration by 1-1.5 days (if started early)
- May reduce complications

**Dosing**:
- **Treatment**: 75 mg BID × 5 days
- **Prophylaxis**: 75 mg daily × 7-10 days (or duration of exposure)

**Adverse Effects**:
- **GI upset**: Nausea, vomiting (common, take with food)
- **Neuropsychiatric events** (rare): Delirium, hallucinations (especially in children/adolescents, Japan)

**Resistance**:
- H275Y mutation (neuraminidase)
- Seasonal H1N1 resistance has occurred

#### Zanamivir (Relenza)

**Administration**:
- **Inhalation** (powder)
- Not absorbed systemically

**Advantages**:
- Less GI upset than oseltamivir
- Less resistance

**Disadvantages**:
- **Bronchospasm risk** (asthma, COPD contraindication)
- Inhalation device required

**Clinical Use**: Alternative to oseltamivir

#### Peramivir (Rapivab)

- **IV neuraminidase inhibitor**
- Single dose for acute influenza
- Used when oral/inhaled not feasible

### M2 Inhibitors (Amantadine, Rimantadine)

**Mechanism**:
- Block M2 ion channel
- Prevent viral uncoating
- **Only active against influenza A** (NOT influenza B)

**Current Status**:
- **Widespread resistance** (>99% of circulating strains)
- **NOT recommended** for influenza treatment or prophylaxis
- **No longer used**

**Other Uses**:
- **Amantadine**: Parkinson's disease, drug-induced extrapyramidal symptoms

---

## Antiretroviral Drugs (HIV)

### Overview

**HIV Life Cycle Targets**:
1. Entry/Fusion
2. Reverse transcription (RNA → DNA)
3. Integration (viral DNA into host genome)
4. Protease (viral polyprotein cleavage)

**ART (Antiretroviral Therapy)**:
- **Combination therapy required** (≥3 drugs from ≥2 classes)
- Suppress viral replication
- ↑CD4 count, ↓viral load
- Prevent progression to AIDS
- Reduce transmission

### Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

**Mechanism**:
- **Prodrugs**: Require intracellular phosphorylation
- Competitive inhibition of reverse transcriptase
- DNA chain terminators (lack 3'-OH group)

**Drugs**: Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TDF/TAF), Abacavir (ABC)

**Class Adverse Effects**:
- **Lactic acidosis** (rare but serious): Mitochondrial toxicity
- **Hepatic steatosis**

#### Tenofovir (Viread)

**Formulations**:
- **TDF** (tenofovir disoproxil fumarate): Original
- **TAF** (tenofovir alafenamide): Newer, lower dose, less toxicity

**Clinical Use**:
- **Backbone of many ART regimens**
- HBV treatment

**Adverse Effects**:
- **Nephrotoxicity** (TDF > TAF): Fanconi syndrome, AKI
- **Bone loss** (TDF > TAF): Osteopenia, osteoporosis
- Monitor: SCr, urine protein, bone density

#### Emtricitabine (FTC, Emtriva)

- Similar to lamivudine (3TC)
- Well-tolerated
- **Co-formulated** with tenofovir (Truvada, Descovy)

#### Abacavir (ABC, Ziagen)

**Unique Toxicity**:
- **Hypersensitivity reaction** (5-8%):
  - Associated with **HLA-B*5701** allele
  - Fever, rash, GI symptoms, respiratory symptoms
  - Can be fatal if rechallenged
  - **Screen for HLA-B*5701** before use (contraindicated if positive)

### Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

**Mechanism**:
- Non-competitive RT inhibitors
- Bind to allosteric site
- **Do NOT require activation**
- **Low genetic barrier** to resistance

**Drugs**: Efavirenz (EFV), Rilpivirine (RPV), Doravirine (DOR), Etravirine (ETR)

#### Efavirenz (Sustiva)

**Advantages**:
- Potent, long half-life (once-daily)

**Adverse Effects**:
- **CNS effects** (50%):
  - Dizziness, insomnia, vivid dreams, hallucinations
  - Usually resolve after 2-4 weeks
  - Take at bedtime
- **Rash**
- **Teratogenic**: Neural tube defects (avoid in 1st trimester pregnancy)
- **False-positive marijuana test**

**Drug Interactions**:
- **CYP3A4 inducer and substrate**

#### Rilpivirine (Edurant)

- Fewer CNS effects than efavirenz
- **Must take with food** (requires gastric acid for absorption)
- **Cannot use with PPIs** (↓absorption)
- Lower genetic barrier than efavirenz

### Protease Inhibitors (PIs)

**Mechanism**:
- Inhibit HIV **protease**
- Prevent cleavage of viral polyproteins
- Produce immature, non-infectious virions

**Drugs**: Darunavir (DRV), Atazanavir (ATV), Lopinavir (LPV)

**All require boosting** with:
- **Ritonavir** (low-dose) or **Cobicistat**
- These inhibit CYP3A4 → ↑PI levels

**Class Adverse Effects**:
- **GI intolerance**: Nausea, diarrhea
- **Metabolic effects**:
  - **Hyperlipidemia** (↑LDL, ↑TG)
  - **Insulin resistance, hyperglycemia**
  - **Lipodystrophy** (fat redistribution)
- **Drug interactions**: Extensive (CYP3A4)

#### Darunavir (Prezista)

- Most commonly used PI
- High genetic barrier to resistance
- Must boost with ritonavir or cobicistat
- Sulfa moiety (caution in sulfa allergy)

### Integrase Strand Transfer Inhibitors (INSTIs)

**Mechanism**:
- Inhibit HIV **integrase**
- Prevent viral DNA integration into host genome

**Drugs**: Dolutegravir (DTG), Bictegravir (BIC), Raltegravir (RAL)

**Advantages**:
- **Highly effective**
- **Well-tolerated**
- **High genetic barrier** to resistance (dolutegravir, bictegravir)
- **Fewer drug interactions** than PIs
- **Preferred regimen component**

**Adverse Effects**:
- Generally minimal
- Insomnia (dolutegravir)
- ↑Creatinine (blocks tubular secretion, not true renal dysfunction)
- Weight gain

**Current Standard**: **Integrase inhibitor-based regimens** are first-line

### Entry/Fusion Inhibitors

**Maraviroc** (CCR5 antagonist):
- Blocks CCR5 coreceptor
- Only for **CCR5-tropic virus** (requires tropism testing)
- Reserved for treatment-experienced patients

**Enfuvirtide** (T-20, fusion inhibitor):
- **Subcutaneous injection** BID
- Reserved for salvage therapy (resistance, limited options)
- Injection site reactions

---

## Hepatitis Antivirals

### Hepatitis B

**Nucleos(t)ide Analogs**:

#### Entecavir (Baraclude)

- Potent HBV polymerase inhibitor
- **High genetic barrier** to resistance
- **Preferred first-line agent**
- Oral, once-daily
- Renal dosing required
- **Monitor**: HBV DNA, ALT, HBeAg

#### Tenofovir (TDF, TAF)

- Also used for HBV (same formulations as HIV)
- **Preferred first-line agent**
- Advantages: High barrier, no HBV resistance reported
- **Monitor**: Renal function, bone density (TDF)

**Older Agents** (less commonly used):
- Lamivudine: High resistance rate
- Adefovir: Nephrotoxic
- Telbivudine: Neuropathy risk

**Interferon**:
- **Pegylated interferon-α**: Finite duration therapy (48 weeks)
- **Adverse effects**: Flu-like symptoms, depression, cytopenias
- Less commonly used now

### Hepatitis C

**Direct-Acting Antivirals (DAAs)**:
- Revolutionized HCV treatment
- **Cure rates >95%**
- Short duration (8-12 weeks)
- Oral, well-tolerated
- Expensive

**Classes**:

1. **NS5A Inhibitors** (end in "-asvir"):
   - Ledipasvir, velpatasvir, pibrentasvir
   - Pan-genotypic

2. **NS5B Polymerase Inhibitors** (end in "-buvir"):
   - Sofosbuvir (nucleotide analog)
   - Pan-genotypic

3. **NS3/4A Protease Inhibitors** (end in "-previr"):
   - Glecaprevir, grazoprevir
   - Genotype-specific

**Common Regimens** (fixed-dose combinations):
- **Sofosbuvir/Velpatasvir** (Epclusa): Pan-genotypic, once-daily, 12 weeks
- **Glecaprevir/Pibrentasvir** (Mavyret): Pan-genotypic, once-daily, 8 weeks
- **Ledipasvir/Sofosbuvir** (Harvoni): Genotype 1, once-daily, 12 weeks

**Adverse Effects**:
- Generally well-tolerated
- Headache, fatigue
- Drug interactions (check carefully)

**Monitoring**:
- HCV RNA at end of treatment and 12 weeks post (SVR12 = sustained virological response = cure)

**Clinical Pearl**: HCV therapy has shifted from interferon-based (poorly tolerated, ~50% cure) to DAA regimens (well-tolerated, >95% cure)

---

## COVID-19 Antivirals

### Remdesivir (Veklury)

**Mechanism**:
- Nucleotide analog
- Inhibits viral RNA polymerase

**Clinical Use**:
- **Hospitalized patients** with COVID-19 requiring oxygen
- IV administration

**Efficacy**:
- Shortens time to recovery
- Mortality benefit unclear

**Adverse Effects**:
- Hepatotoxicity
- Infusion reactions
- Renal impairment

### Nirmatrelvir/Ritonavir (Paxlovid)

**Mechanism**:
- Nirmatrelvir: SARS-CoV-2 protease inhibitor
- Ritonavir: Boosts nirmatrelvir levels (CYP3A4 inhibition)

**Clinical Use**:
- **Outpatients** with mild-moderate COVID-19
- High risk for progression
- **Within 5 days** of symptom onset

**Efficacy**:
- ↓Hospitalization/death by ~89%

**Adverse Effects**:
- Dysgeusia (altered taste) - very common
- **Extensive drug interactions** (ritonavir = potent CYP3A4 inhibitor)
- **Rebound** phenomenon (10-15% after completion)

**Drug Interactions**:
- Contraindicated with many drugs (check interactions)
- Adjust statins, immunosuppressants, etc.

### Molnupiravir (Lagevrio)

**Mechanism**:
- Nucleoside analog
- Induces viral mutations (error catastrophe)

**Clinical Use**:
- **Outpatients** with mild-moderate COVID-19
- Alternative when Paxlovid contraindicated/unavailable

**Efficacy**:
- ↓Hospitalization/death by ~30% (less than Paxlovid)

**Adverse Effects**:
- Generally well-tolerated
- Theoretical mutagenicity concerns

---

## Clinical Pearls - Summary

1. **Acyclovir**: HSV/VZV, hydrate with IV use, safe in pregnancy
2. **Ganciclovir**: CMV, bone marrow suppression (monitor CBC)
3. **Oseltamivir**: Influenza, start within 48 hours for benefit
4. **HIV ART**: Combination therapy required, INSTIs preferred first-line
5. **HCV DAAs**: >95% cure, pan-genotypic regimens available
6. **HBV**: Entecavir or tenofovir first-line (high resistance barrier)
7. **Resistance**: Major challenge; combination therapy prevents (HIV, HCV)
8. **Drug interactions**: Especially PIs, NNRTIs (CYP450)
9. **Paxlovid**: Most effective outpatient COVID-19 treatment, extensive drug interactions
10. **Monitor adherence**: Essential for viral suppression and preventing resistance

---

## Key Takeaways

1. **Selective toxicity** challenging due to viral dependence on host machinery
2. **Acyclovir/valacyclovir**: Mainstay of HSV/VZV therapy
3. **Ganciclovir/valganciclovir**: CMV treatment, myelosuppression risk
4. **Neuraminidase inhibitors**: Influenza treatment (oseltamivir), early initiation key
5. **HIV ART**: Combination therapy, INSTI-based regimens preferred
6. **HCV DAAs**: Revolutionized treatment, >95% cure rates
7. **HBV**: Entecavir or tenofovir for high resistance barrier
8. **Resistance**: Prevented by combination therapy (HIV, HCV)
9. **Drug interactions**: Extensive with PIs, ritonavir-boosted regimens
10. **Adherence**: Critical for efficacy and preventing resistance

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. DHHS Guidelines for Antiretroviral Drugs in HIV-Infected Adults and Adolescents, 2024
4. AASLD-IDSA HCV Guidance, 2024
5. IDSA Influenza Guidelines, 2023
6. NIH COVID-19 Treatment Guidelines, 2024
